Drugging Cancers Big Four
What does it mean to drug cancer’s “big four”? Learn how Darryl McConnell & his team are tackling one of the biggest scientific conundrums.
Search
The Supplier Code of Conduct
BI’s expectations towards its suppliers on ethical behavior, integrity, professionalism and common business requirements.
Our Approach
We are driven by the desire to improve human and animal health -– now and in the future. Therefore, we have developed our framework: Sustainable Development – For Generations.
Local healthcare community raise alarm bells on growing trend of cardiovascular disease risk
Local healthcare community raise alarm bells on growing trend of cardiovascular disease risk factors associated with type 2 diabetes
Prevention of Schizophrenia
Can schizophrenia be prevented?That’s what investigators are hoping to find out, according to scientists attending the American College of Neuropsychopharmacology (ACNP) in Orlando, Florida.[node:body][node:title]
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Rare Diseases: Rare but not alone
We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.
International Women's Day
We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”
Lead with Pride – for the Benefit of All.
How Inclusive Leadership advocates for Acceptance and creating a Sense of Belonging
Retinal Health Research
Read about our holistic approach to retinal health research.
Trust Through Transparency
Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic
Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic Pulmonary Fibrosis in the Region
New approaches in the battle against heartworm disease
Heartworm disease is a concern to dog and cat owners worldwide. Current disease control methods are increasingly challenged by drug resistance. We explore the potential for novel treatments and vaccines based on new knowledge and technology.
More Potential Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
The Neuroscience Gallery
Take a guided tour through our virtual 3-D Neuroscience art exhibition, with Clinical Program Leader, Dr. Michael Sand.
Empowering and Upskilling Patient Organizations in the IMETA Region
Boehringer Ingelheim held the first PULSE training programme in Dubai, bringing together over twenty representatives of patient organizations from across India, the Middle East, Turkey, and Africa.
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting the Importance of an Integrated Approach to Treat Type 2 Diabetes
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
Regional experts highlight need for coordinated, collaborative efforts in stroke care through
Regional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital unitsRegional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital units
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Congress Patient Benefit
The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Taking cancer on with smart combinations
Boehringer Ingelheim digs deep into the science and taking a precision approach to develop smart combinations to bring the greatest benefit to patients.
Parasites: What your pets can’t tell you!
Learn how our team in the East & Southeast Asia approached the topic of pet parasite issues in the region.